Company news

Regeneron Pharmaceuticals, Inc. news in 2020

Regeneron Pharmaceuticals, Inc.'s news releases, calls and decks from 2020, newest first.

View company

Regeneron Announces Encouraging Initial Data from COVID-19 Antibody Cocktail Trial in Hospitalized Patients on Low-flow Oxygen

December 28, 2020

Regeneron Announces Presentation at the 39th Annual J.P. Morgan Healthcare Conference

December 15, 2020

Regeneron's BCMAxCD3 Bispecific Antibody (REGN5458) Shows Deep and Durable Responses in Patients with Heavily-pretreated Multiple Myeloma in Phase 1

December 4, 2020

Dupixent® (dupilumab) Approved by European Commission as First and Only Biologic Medicine for Children Aged 6 to 11 Years with Severe Atopic Dermatitis

November 29, 2020

Regeneron's REGEN-COV2 is First Antibody Cocktail for COVID-19 to Receive FDA Emergency Use Authorization

November 20, 2020

Regeneron Reports Third Quarter 2020 Financial and Operating Results

November 4, 2020

REGN-COV2 Independent Data Monitoring Committee Recommends Holding Enrollment in Hospitalized Patients with High Oxygen Requirements and Continuing Enrollment in Patients with Low or No Oxygen Requirements

October 29, 2020

FDA Accepts for Priority Review Libtayo® (cemiplimab-rwlc) for Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50%

October 28, 2020

Regeneron's COVID-19 Outpatient Trial Prospectively Demonstrates that REGN-COV2 Antibody Cocktail Significantly Reduced Virus Levels and Need for Further Medical Attention

October 27, 2020

Regeneron's Antibody Cocktail REGN-EB3 (Inmazeb®) is First FDA-Approved Treatment for Ebola (Zaire Ebolavirus)

October 13, 2020

Regeneron to Report Third Quarter 2020 Financial and Operating Results and Host Conference Call and Webcast on November 5, 2020

October 5, 2020

Regeneron's REGN-COV2 Antibody Cocktail Reduced Viral Levels and Improved Symptoms in Non-Hospitalized COVID-19 Patients

September 28, 2020

RECOVERY COVID-19 Phase 3 Trial to Evaluate Regeneron's REGN-COV2 Investigational Antibody Cocktail in the UK

September 13, 2020

Regeneron and Roche Collaborate to Significantly Increase Global Supply of REGN-COV2 Investigational Antibody Cocktail for COVID-19

August 18, 2020

FDA Accepts Evinacumab Biologics License Application for Priority Review as a Treatment for Patients with HoFH, an Ultra-rare Inherited Form of High Cholesterol

August 11, 2020

Regeneron Announces Pricing of Public Offering of Senior Unsecured Notes

August 6, 2020

Regeneron Reports Second Quarter 2020 Financial and Operating Results

August 4, 2020

BARDA Procures Regeneron's REGN-EB3 Investigational Ebola Treatment for National Preparedness

July 28, 2020

Regeneron to Report Second Quarter 2020 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2020

July 7, 2020

Regeneron Announces Manufacturing and Supply Agreement for BARDA and U.S. Department of Defense for REGN-COV2 Anti-Viral Antibody Cocktail

July 6, 2020

Regeneron Announces Start of REGN-COV2 Phase 3 COVID-19 Prevention Trial in Collaboration with National Institute of Allergy and Infectious Diseases (NIAID)

July 5, 2020

Regeneron and Sanofi Provide Update on Kevzara® (sarilumab) Phase 3 U.S. Trial in COVID-19 Patients

July 1, 2020

Regeneron Announces the 2020 Winners of the Regeneron Prize for Creative Innovation

June 21, 2020

FDA Approves New Dupixent® (dupilumab) Pre-filled Pen Designed to Support More Convenient Self-Administration

June 18, 2020

Regeneron Begins First Clinical Trials of Anti-Viral Antibody Cocktail REGN-COV2 for the Treatment and Prevention of COVID-19

June 10, 2020

Regeneron Announces Virtual-Only Format for 2020 Annual Meeting of Shareholders

June 7, 2020

Regeneron Announces Upcoming Investor Conference Presentations

June 4, 2020

Regeneron and Intellia Therapeutics Expand Collaboration to Develop CRISPR/Cas9-Based Treatments

May 31, 2020

Regeneron Completes Secondary Offering of Common Stock Held by Sanofi

May 28, 2020

Regeneron Announces Pricing of Secondary Offering of its Common Stock Held by Sanofi

May 25, 2020

Regeneron Announces Secondary Offering of its Common Stock Held by Sanofi and $5 Billion Stock Repurchase

May 24, 2020

Regeneron and Colorado Center for Personalized Medicine Announce Major New Human Genetics Research Collaboration

May 10, 2020

Regeneron Reports First Quarter 2020 Financial and Operating Results

May 4, 2020

Regeneron and Sanofi Provide Update on U.S. Phase 2/3 Adaptive-Designed Trial of Kevzara® (sarilumab) in Hospitalized COVID-19 Patients

April 26, 2020

FDA Accepts for Priority Review Biologics License Application for REGN-EB3 to Treat Ebola

April 15, 2020

Regeneron and Zai Lab Announce Regional Strategic Collaboration for REGN1979 (CD20xCD3 Bispecific Antibody)

April 7, 2020

Regeneron Finalizes Praluent® (alirocumab) Restructuring and Updates Accounting Presentation

April 5, 2020

Dupixent® (dupilumab) Phase 3 Data at Revolutionizing Atopic Dermatitis Conference Show Significant Improvement in Severe Atopic Dermatitis for Children Aged 6 to 11 Years

April 2, 2020

Regeneron Announces American College of Cardiology Presentation of Positive Phase 3 Evinacumab Results in Patients with Severe Inherited Form of High Cholesterol

March 29, 2020

Calls in 2020

Decks in 2020